Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) reveal a somatostatin receptor-expressing meningioma within the left cavernous sinus (white and black arrows). After 4 cycles of peptide receptor radionuclide remedy (PRRT), a whole remission in response to the Response Evaluation in Neuro-Oncology in addition to PET standards was recorded (proper). Scale bars denote standardized uptake values. Credit score: A Amerein, M Kircher, C Lapa, et al., College of Augsburg, Augsburg, Germany.
Radionuclide remedy delivered on to an artery is protected and possible for sufferers with superior meningioma, in response to new analysis printed within the December challenge of The Journal of Nuclear Drugs. Within the first long-term examine of intraarterial peptide receptor radionuclide remedy (PRRT) in superior meningioma, sufferers noticed improved radiologic and medical illness management in contrast with intravenous PRRT, with no extra toxicity.
Meningiomas are the commonest major neoplasms of the central nervous system and account for greater than one-third of all circumstances. Meningiomas are largely labeled as benign, however 10–15% of circumstances are thought-about atypical or malignant. The popular remedy is surgical procedure with exterior beam radiotherapy. Nevertheless, 30–40% of lesions are ineligible for surgical procedure as a result of their location. Moreover, recurrence charges are notably excessive.
“For meningioma patients who are ineligible for surgery or who experience tumor recurrence, treatment options are limited,” acknowledged Adriana Amerein, MD, nuclear medication resident at College Hospital Augsburg in Augsburg, Germany. “Due to the high expression of somatostatin receptors in most meningiomas, radiopharmaceutical therapy offers a viable therapeutic alternative for patients. Intraarterial administration of the radiopharmaceutical might boost the achievable radiation dose to the tumor.”
Within the examine, researchers assessed the long-term security and efficacy of intraarterial PRRT in sufferers with superior, progressive meningioma. 13 sufferers underwent one to 4 cycles of intraarterial PRRT with 177Lu-HA-DOTATATE. Security and remedy response was evaluated in response to medical standards, and outcomes had been in contrast with intravenous PRRT.
Therapy with intraarterial PRRT was nicely tolerated, with solely transient adversarial results. The median progression-free survival for intraarterial PRRT was 18 months, and the median total survival was not reached after 43 months. Roughly 80% of the sufferers confirmed radiologic illness management after intraarterial PRRT, in comparison with 40% after intravenous PRRT.
“These findings show that intraarterial administration of radiopharmaceutical therapy in meningioma is feasible, safe, and could be a promising therapeutic option in the future,” stated Constantin Lapa, MD, nuclear medication doctor at College Hospital Augsburg. “Looking forward, personalized dosing and combination therapies utilizing intraarterial PRRT could further improve results for patients who don’t respond to conventional therapies.”
Extra info:
Adriana Amerein et al, Intraarterial Administration of Peptide Receptor Radionuclide Remedy in Sufferers with Superior Meningioma: Preliminary Security and Efficacy, Journal of Nuclear Drugs (2024). DOI: 10.2967/jnumed.124.268217
Offered by
Society of Nuclear Drugs and Molecular Imaging
Quotation:
Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers (2024, December 11)
retrieved 11 December 2024
from https://medicalxpress.com/information/2024-12-intraarterial-radionuclide-therapy-safe-effective.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
